新辅助系统治疗后乳腺癌手术范式的消除:当前证据与未来挑战
本文讨论可手术早期乳腺癌患者接受新辅助系统治疗(NST)后,基于反应调整手术的四个关键问题。文章聚焦于识别病理完全缓解(pCR)的诊断工具结局指标、以最低并发症和最佳准确性评估反应的方法、依赖非手术诊断pCR可能遗漏微小残留病的肿瘤学后果,以及手术降阶梯临床试验的设计。
要点
- NST适应症已从局部晚期降期扩展至体内药敏检测。
- 反应模式用于调整系统与局部治疗,非反应者升阶、反应者降阶。
- 需明确诊断工具识别pCR的关键结局指标及非手术诊断的风险。
核心结论
- 基于NST反应调整乳腺癌手术需解决诊断准确性、肿瘤学安全性和试验设计等关键问题。
研究设计与样本
- 本文为综述性讨论,围绕四个临床问题展开分析,未报告系统检索范围或样本量。
主要发现
- NST适应症从局部晚期降期扩展至体内药敏检测,反应模式用于治疗升阶或降阶。
- 依赖非手术诊断pCR可能在某些病例中遗漏微小残留病。
临床怎么用
- 临床可依据NST反应模式调整系统与局部治疗,对非反应者升阶、对反应者考虑降阶。
- 采用非手术诊断pCR前需权衡遗漏微小残留病的风险。
局限性
- 本文为观点性讨论,未提供系统检索策略或原始研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with operable early breast cancer, neoadjuvant systemic treatment (NST) is a standard approach. Indications have expanded from downstaging of locally advanced breast cancer to facilitate breast conservation, to in vivo drug-sensitivity testing. The pattern of response to NST is used to tailor systemic and locoregional treatment, that is, to escalate treatment in nonresponders and de-escalate treatment in responders. Here we discuss four questions that guide our current thinking about 'response-adjusted' surgery of the breast after NST. (i) What critical diagnostic outcome measures should be used when analyzing diagnostic tools to identify patients with pathologic complete response (pCR) after NST? (ii) How can we assess response with the least morbidity and best accuracy possible? (iii) What oncological consequences may ensue if we rely on a nonsurgical-generated diagnosis of, for example, minimally invasive biopsy proven pCR, knowing that we may miss minimal residual disease in some cases? (iv) How should we design clinical trials on de-escalation of surgical treatment after NST?
引用
- Heil J, Kuerer HM, Pfob A, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020. PMID: 31912797. doi:10.1016/j.annonc.2019.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。